title: [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
abstract: Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin.Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance.In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.
authors.affiliation: 3. Medizinische Abteilung, Kardiologie und internistische Intensivmedizin, Wilhelminenspital, Montleartstraße 37, 1160 Wien, Österreich. thomas.weiss@meduniwien.ac.at.|Medizinische Fakultät, Sigmund Freud Universität, Wien, Österreich. thomas.weiss@meduniwien.ac.at.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Weiss
authors.affiliation: 3. Medizinische Abteilung, Kardiologie und internistische Intensivmedizin, Wilhelminenspital, Montleartstraße 37, 1160 Wien, Österreich.
authors.forename: Miklos
authors.identifier: http://orcid.org/0000-0002-8967-0806
authors.initials: M
authors.lastname: Rohla
authors.affiliation: Zentrallabor, Konventhospital Barmherzige Brüder Linz, Seilerstätte 2, 4021, Linz, Österreich.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Dieplinger
authors.affiliation: Universitätsklinik für Notfallmedizin, Allgemeines Krankenhaus der Stadt Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
authors.forename: Hans
authors.initials: H
authors.lastname: Domanovits
authors.affiliation: Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin, Anichstraße 35, 6020, Innsbruck, Österreich.
authors.forename: Dietmar
authors.initials: D
authors.lastname: Fries
authors.affiliation: Klinik für Neurologie 2, Med Campus III, Kepler Universitätsklinikum, Krankenhausstr. 9, 4020, Linz, Österreich.
authors.forename: Milan R
authors.initials: MR
authors.lastname: Vosko
authors.affiliation: Klinische Abteilung für Angiologie, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.
authors.forename: Thomas
authors.initials: T
authors.lastname: Gary
authors.affiliation: Klinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
authors.forename: Cihan
authors.initials: C
authors.lastname: Ay
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants; D001281:Atrial Fibrillation / Q000517:prevention & control; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D020521:Stroke; D013844:Thiazoles / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; C552171:edoxaban
keywords: Atrial fibrillation; Edoxaban; Non-Vitamin K antagonist oral anticoagulants; Venous thromboembolism